<DOC>
	<DOCNO>NCT01086813</DOCNO>
	<brief_summary>Phase I , Single Centre , Open Label Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics Intravenous AZD3043 aSingle Ascending Bolus Dose Followed Single Infusion Dose Elderly ( =65 year ) Healthy Volunteers</brief_summary>
	<brief_title>Phase I , Single Centre , Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics AZD3043</brief_title>
	<detailed_description>Phase I , Single Centre , Open Label Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics Intravenous AZD3043 Single Ascending Bolus Dose Followed Single Infusion Dose Elderly ( =65 year ) Healthy Volunteers</detailed_description>
	<criteria>Preanaesthesia assessment judge without remark investigator . ASA physical status category 1 2 ( include 3 depend applicable patient category ) Lack normal range enzyme activity BuChE Known suspect history hypersensitivity drug similar chemical structure class AZD3043 ( e.g. , emulsionbased product like Diprivan , Intralipid ) , allergy soybean peanut product drug intend use th Prolonged QTcF &gt; 450 m shorten QTcF &lt; 350 m family history long QT syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sedation</keyword>
</DOC>